Processa Pharmaceuticals (PCSA) Change in Cash (2012 - 2026)

Processa Pharmaceuticals (PCSA) has 15 years of Change in Cash data on file, last reported at -$3.8 million in Q1 2026.

• Quarterly Change in Cash fell 325.47% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 million (up 79.98% YoY) and the FY2025 annual result came in at $4.3 million, up 223.64% from the prior year.
• Change in Cash slipped to -$3.8 million in Q1 2026, from -$771465.0 in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $4.2 million in Q1 2023 to a low of -$3.8 million in Q1 2026.
• A 5-year average of -$870972.8 and a median of -$2.1 million in 2023 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash jumped 301.53% — and 2026, when it sank 325.47%.
• Tracing PCSA's Change in Cash over 5 years: stood at -$2.6 million in 2022, then rose by 15.54% to -$2.2 million in 2023, then gained by 21.09% to -$1.7 million in 2024, then soared by 54.62% to -$771465.0 in 2025, then slumped by 398.52% to -$3.8 million in 2026.
• The last three Change in Cash figures came in at -$3.8 million (Q1 2026), -$771465.0 (Q4 2025), and -$628200.0 (Q3 2025), per Business Quant data.